Alimera Sciences, Inc. (ALIM)
Stock Price:
$4.35 USD
0.15 (3.57%)
Updated Oct 30, 2020 12:38 PM EDT - Market open
Key Info
| Market Cap |
21.89M |
| Revenue (ttm) |
54.77M |
| Net Income (ttm) |
-6.39M |
| Shares Out |
5.03M |
| EPS (ttm) |
-1.30 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$4.35 |
| Previous Close |
$4.20 |
| Change ($) |
0.15 |
| Change (%) |
3.57% |
| Day's Open |
4.11 |
| Day's Range |
4.11 - 4.45 |
| Day's Volume |
2,329 |
| 52-Week Range |
0.00 - 9.98 |
More Stats
| Market Cap |
21.89M |
| Enterprise Value |
52.30M |
| Earnings Date (est) |
Mar 3, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
5.03M |
| Float |
4.43M |
| EPS (basic) |
-1.29 |
| EPS (diluted) |
-1.30 |
| FCF / Share |
-0.72 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
31,489 |
| Short Ratio |
2.21 |
| Short % of Float |
0.71% |
| Beta |
2.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.40 |
| PB Ratio |
n/a |
| Revenue |
54.77M |
| Operating Income |
-1.37M |
| Net Income |
-6.39M |
| Free Cash Flow |
-3.61M |
| Net Cash |
-30.41M |
| Net Cash / Share |
-6.04 |
| Gross Margin |
86.39% |
| Operating Margin |
-2.50% |
| Profit Margin |
-11.70% |
| FCF Margin |
-6.59% |
| ROA |
-1.94% |
| ROE |
n/a |
| ROIC |
-2.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.50*
(210.34% upside)
Low
10.0
Current: $4.35
High
18.0
Target: 13.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 53.94 | 46.60 | 35.91 | 34.33 | 22.44 | 8.42 | 1.87 | - | - | - |
| Revenue Growth | 15.76% | 29.76% | 4.6% | 53.01% | 166.39% | 349.95% | - | - | - | - |
| Gross Profit | 47.32 | 42.29 | 32.47 | 31.99 | 20.68 | 6.98 | 0.01 | - | - | - |
| Operating Income | -5.27 | -9.67 | -16.45 | -27.85 | -39.00 | -32.95 | -34.40 | -22.04 | -21.41 | -22.07 |
| Net Income | -10.44 | -16.38 | -22.00 | -33.17 | -30.65 | -35.91 | -46.23 | -19.75 | -22.52 | -13.86 |
| Shares Outstanding | 4.77 | 5.87 | 4.47 | 3.52 | 2.96 | 2.69 | 2.11 | 2.10 | 2.09 | 1.48 |
| Earnings Per Share | -2.19 | 3.71 | -4.95 | -9.45 | -10.35 | -13.65 | -24.30 | -9.45 | -10.80 | -11.55 |
| Operating Cash Flow | -4.15 | -11.55 | -12.87 | -25.10 | -45.36 | -24.30 | -37.82 | -21.18 | -20.72 | -22.05 |
| Capital Expenditures | -0.17 | -0.18 | -0.24 | -0.19 | -0.45 | -0.84 | -0.97 | -0.02 | -0.11 | -0.13 |
| Free Cash Flow | -4.33 | -11.73 | -13.11 | -25.29 | -45.82 | -25.14 | -38.79 | -21.21 | -20.83 | -22.18 |
| Cash & Equivalents | 9.46 | 13.08 | 24.10 | 31.01 | 31.11 | 76.70 | 12.63 | 49.56 | 33.61 | 54.84 |
| Total Debt | 39.01 | 38.41 | 34.75 | 33.55 | 32.60 | 33.35 | 4.87 | 2.98 | 5.34 | 5.94 |
| Net Cash / Debt | -29.55 | -25.34 | -10.65 | -2.54 | -1.49 | 43.34 | 7.76 | 46.58 | 28.27 | 48.91 |
| Assets | 50.31 | 54.11 | 59.92 | 70.23 | 70.48 | 109 | 19.62 | 52.52 | 34.70 | 56.41 |
| Liabilities | 54.75 | 51.39 | 45.01 | 44.64 | 44.16 | 59.14 | 24.55 | 13.38 | 9.72 | 11.20 |
| Book Value | -4.45 | 2.72 | 14.92 | 25.59 | 26.32 | 49.52 | -4.93 | 39.14 | 24.98 | 45.21 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Alimera Sciences, Inc. |
| Country |
United States |
| Employees |
122 |
| CEO |
Richard S. Eiswirth |
Stock Information
| Ticker Symbol |
ALIM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: ALIM |
| IPO Date |
April 22, 2010 |
Description
Alimera Sciences, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.